TMCnet News
Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology ConferenceCAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that the Company will participate in the Bank of America 2022 Precision Oncology Conference, which will be held virtually on October 3rd, 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. Fireside chat date and time: Monday, October 3rd, 2022, at 12:20 p.m. ET Please find a link to the fireside chat here. A webcast of the fireside chat and presentation will be accessible under “Events & Presentations” in the Investors section of the Company’s website, www.foghrntx.com, and will remain available for up to 90 days. About Foghorn Therapeutics Contact: Ben Strain, Foghorn Therapeutics Inc. (Media and Investors) Karin Hellsvik, Foghorn Therapeutics Inc. (Media) Michael Lampe, ScientPR (Media) Hans Vitzthum, LifeSci Advisors (Investors) |